Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board:
Last Post: 8/28/2016 9:30:17 PM - Followers: 832 - Board type: Free - Posts Today: 110

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Statement of Changes in Beneficial Ownership (4) 08/19/2016 05:48:03 PM
ELTP News: Four Trending Stocks Leading Biotech Sector on Heels of Latest R&D and Innovative Drug Therapy Advancements 07/27/2016 09:00:00 AM
ELTP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 07/21/2016 11:47:37 AM
ELTP News: Current Report Filing (8-k) 07/21/2016 07:16:35 AM
ELTP News: Friendable, Inc. (OTC Pink: FDBL) – Ramps Up Infrastructure To Accommodate Growth 07/19/2016 08:00:00 AM
#222196  Sticky Note Freedom of Information Act Request to FDA WeeZuhl 08/17/16 07:21:46 AM
#220115  Sticky Note Nasrat: “their concern is that this is instant elichen 08/06/16 03:05:48 AM
#217429  Sticky Note Here is the TRUTH about T-max-SEC-Filed! Drugdoctor 07/25/16 06:43:08 AM
#207474  Sticky Note These people cannot be help by the FDA lasers 06/24/16 06:10:52 PM
#200119  Sticky Note Dear WeeZuhl, WeeZuhl 05/15/16 10:56:35 AM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#224200   Elite will be granted the BEST ADF labeling NASDAQ2020 08/28/16 09:30:17 PM
#224199   I've been hearing the same BS since .06. Couch 08/28/16 09:28:19 PM
#224198   Uh huh sure k. Couch 08/28/16 09:27:32 PM
#224197   Obviously nobody does. Next Couch 08/28/16 09:26:45 PM
#224196   What did the FDA say in the Type Couch 08/28/16 09:25:39 PM
#224195   I never agree with anything you say or rocioyogi 08/28/16 09:25:22 PM
#224194   Let us know how that $1 million unsecured Couch 08/28/16 09:23:45 PM
#224193   Multi years of OTC trading experience so I Couch 08/28/16 09:22:20 PM
#224192   Once SequestOx™ is approved it will be extremely NASDAQ2020 08/28/16 09:18:11 PM
#224191   Does Micah also buy the pens, pencils and namtae 08/28/16 09:11:06 PM
#224190   More like $25 million for Mikah Pharma and John_Langston 08/28/16 08:41:28 PM
#224189   Interesting but zero proof that they wanted elite. dr_lowenstein 08/28/16 08:24:24 PM
#224188   Sounds good. YJ4LIFE 08/28/16 08:23:34 PM
#224187   Shareholders getting BAGGED by the ceo imo Buyouts? Partnerships? namtae 08/28/16 08:17:45 PM
#224186   Correct that's why nasRAT is abusing Elite by John_Langston 08/28/16 08:11:22 PM
#224185   those 2 events put together in such a John_Langston 08/28/16 08:06:55 PM
#224184   How is that working out!!! John_Langston 08/28/16 08:04:39 PM
#224183   Nasrat stated on the recent CC John_Langston 08/28/16 08:03:06 PM
#224182   Multi years of OTC trading experience so I John_Langston 08/28/16 08:00:54 PM
#224181   That would be great if NasRAT came clean. John_Langston 08/28/16 07:49:39 PM
#224180   Well you've waited long enough how does 550 rocioyogi 08/28/16 07:45:02 PM
#224179   I've been hearing this Elite merger crap for IB_ 08/28/16 07:41:09 PM
#224178   I really believe the Naz and a few rocioyogi 08/28/16 07:37:34 PM
#224177   Excellent DD. lasers 08/28/16 07:17:44 PM
#224176   With the aforementioned, I have a question for no2koolaid 08/28/16 07:14:20 PM
#224175   I would agree that the scenarios for Elite no2koolaid 08/28/16 07:06:08 PM
#224174   Just to be strategy specific on M&A, it no2koolaid 08/28/16 06:57:48 PM
#224173   Whole lot of BS being spread about Elite namtae 08/28/16 06:56:00 PM
#224172   Not a problem at all as Teva/Allergan would lasers 08/28/16 06:33:35 PM
#224171   Part of the agreement, Micah has a NASDAQ2020 08/28/16 06:31:05 PM
#224170   TOTAL and UTTER BS. You do realize that Couch 08/28/16 06:17:59 PM
#224169   Nasrat is abusing Elite interpositioning Micah between generic namtae 08/28/16 06:10:49 PM
#224168   They bought trimipramine MR ELITE 08/28/16 05:50:16 PM
#224167   You do realize those 2 events put together Couch 08/28/16 05:41:00 PM
#224166   Gee the last 2 CCs. Couch 08/28/16 05:36:41 PM
#224165   Total BS. Nasrat stated on the recent CC Couch 08/28/16 05:34:27 PM
#224164   CRL has resolved it for Sequest...its OVER!! Couch 08/28/16 05:31:20 PM
#224163   Nice find. nasRAT can't stop showing his true colors. Couch 08/28/16 05:14:27 PM
#224162   Multi years of executive Pharma experience so I lasers 08/28/16 04:51:08 PM
#224161   Of total useless value as it means nothing. lasers 08/28/16 04:48:58 PM
#224159   Ok that's great if true, but you info cicle1 08/28/16 04:47:28 PM
#224158   Material event solutions are being worked on in lasers 08/28/16 04:45:37 PM
#224157   good thinking!! it is known as the Elite dr_lowenstein 08/28/16 04:17:45 PM
#224156   Here's a fact since sesspoolOX has been announced stockboy 08/28/16 04:15:34 PM
#224155   Agree on a partnership part, but don't agree cicle1 08/28/16 04:14:36 PM
#224153   PURE speculation! PEOPLE there is no PARTNERSHIP coming stockboy 08/28/16 04:11:39 PM
#224152   That would be great if NasRAT came clean. stockboy 08/28/16 04:09:16 PM
#224151   Good find..Unfortunate, but nice one. 3ch0 08/28/16 04:09:10 PM
#224150   CRL has resolved it for Sequest...its OVER!! namtae 08/28/16 03:56:54 PM
#224149   CRL has resolved it for Sequest...its OVER!! namtae 08/28/16 03:56:54 PM